• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Matthias Cheung, PhD, Discusses Current Federal Legislation and Ongoing Policies Regarding Orphan Drugs and Rare Disease

Article

Matthias Cheung, PhD, FCSHP, FASHP, a principal at Advanced Rx Consulting, LLC, and an adjunct professor of pharmacy practice at the University of the Pacific, Thomas J. Long School of Pharmacy and Health Services, discusses the circumstances and factors that catalyzed the passage of current legislation and regulatory policies for orphan drugs, rare diseases, and ultra-rare diseases.

Matthias Cheung, PhD, FCSHP, FASHP, a principal at Advanced Rx Consulting, LLC, and an adjunct professor of pharmacy practice at the University of the Pacific, Thomas J. Long School of Pharmacy and Health Services, discusses the circumstances and factors that catalyzed the passage of current legislation and regulatory policies for orphan drugs, rare diseases, and ultra-rare diseases.

This video was taken at the Academy of Managed Care Pharmacy's 25th Annual Meeting & Expo in San Diego, CA, on April 5, 2013.

Related Videos
Khush Kharidia, MD
Kimberly Westrich, MA, chief strategy officer, National Pharmaceutical Council
Harry Travis, BS Pharm, MBA, president at The Travis Group, LLC
 Brigid Groves, PharmD, MS, vice president, professional affairs, American Pharmacists Association
Chelsea Renfro, PharmD, research and engagement pharmacist, Vanderbilt Specialty Pharmacy
Chicago skyline with words "CHEST 2025 Recap Chicago, Illinois" | Image credit: SeanPavonePhoto - stock.adobe.com
Screenshot of an interview with Kristina Crothers, MD
James Simon, MD – Image credit: AJMC
Brooke Aggarwal, EdD – screenshot by AJMC
JoAnn Pinkerton, MD
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.